Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Damora Therapeutics initiated the Phase 1/1b clinical trial of its lead candidate DMR-001 targeting mutant calreticulin-driven blood disorders, presenting strong preclinical data at EHA 2026. The company enhanced its governance by adding Dr. Andrew Cheng to the board, and maintains a robust cash position of $540.5 million, funding operations into l…